openPR Logo
Press release

RNA Based Therapeutics Market Expected to grow at a CAGR of CAGR of 28.5% By Key Players: Quark Pharmaceuticals, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Tekmira Pharmaceuticals

07-09-2019 07:25 PM CET | Health & Medicine

Press release from: Supply Demand Market Research

RNA Based Therapeutics Market

RNA Based Therapeutics Market

RNA Based Therapeutics Market research report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market.
The Global RNA based therapeutics Market has garnered significant attention in the recent years due to its potential to treat variety of chronic diseases such as cancer, diabetes, AIDS, Tuberculosis and certain cardiovascular conditions.
Despite the restraints, RNA based therapeutics has the potential to grow due to increasing interest exhibited by the pharmaceutical industries for the commercialization of these therapies.
Download Sample PDF copy of this report @ https://www.supplydemandmarketresearch.com/home/contact/491567?ref=Sample-and-Brochure&toccode=SDMRME491567&utm_source=S2
Despite being in the clinical research phase, the RNA based therapeutics is been explored as a promising treatment option for the diseases which are difficult to treat.Development of this therapeutics is based on promising technologies such as RNA interference technology (RNAi), antisense technology and SMaRT technology. RNAi technology and antisense technology together are gaining prominence in the research industry, as these technologies provide base sequence to develop RNA drugs. RNAi technology works by causing destruction of specific mRNA molecules; whereas, antisense technology works by synthesizing strand of RNA from known gene sequence. These newly synthesized RNA strands then itself binds to mRNA and make mRNA inactive. Gene silencing potential of RNA based therapeutics is the primary driver for the growth of this market. The other drivers include target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, critical issues in drug delivery, high cost of research, and high failure rates are some of the major hurdles for the companies working in this field.
This of report focuses on the RNA Based Therapeutics Market in global market, especially in United States, China, Europe, Japan, Southeast Asia, India and more.
The Top key players covered in this study:
Quark Pharmaceuticals
Alnylam Pharmaceuticals
Dicerna Pharmaceuticals
Tekmira Pharmaceuticals
Benitec Biopharma Limited and more….
Market Segment by Type, covers:
Microarrays
Labeling
Purification
Linear amplification
qRT-PCR
Inhibition
RNA Interference (RNAi) technologies
RNA antisense technologies
Market Segment by Applications, can be divided into:
Cardiovascular
Kidney Diseases
Oncology
Infectious diseases
Metabolic disorders
Others
qRT-PCR
Inhibition
RNA Interference (RNAi) technologies
RNA antisense technologies
Enquire before purchase@: https://www.supplydemandmarketresearch.com/home/purchase?code=SDMRME491567
Table of Contents:
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.3 Industrial Chain
1.4 Industry Situation
1.5 SWOT Analysis
2 Market Analysis by Types
2.1 Overall Market Performance(Volume)
2.2 Overall Market Performance(Value)
3 Product Application Market
3.1 Overall Market Performance (Volume)
4 Manufacturers Profiles/Analysis
4.1 Quark Pharmaceuticals
4.1.1 Quark Pharmaceuticals Profiles
4.1.2 Quark Pharmaceuticals Product Information
4.1.3 Quark Pharmaceuticals RNA Based Therapeutics Business Performance
4.1.4 Quark Pharmaceuticals RNA Based Therapeutics Business Development and Market Status
4.2 Alnylam Pharmaceuticals
4.2.1 Alnylam Pharmaceuticals Profiles
4.2.2 Alnylam Pharmaceuticals Product Information
4.2.3 Alnylam Pharmaceuticals RNA Based Therapeutics Business Performance
4.2.4 Alnylam Pharmaceuticals RNA Based Therapeutics Business Development and Market Status
4.3 Dicerna Pharmaceuticals
4.3.1 Dicerna Pharmaceuticals Profiles
4.3.2 Dicerna Pharmaceuticals Product Information
4.3.3 Dicerna Pharmaceuticals RNA Based Therapeutics Business Performance
4.3.4 Dicerna Pharmaceuticals RNA Based Therapeutics Business Development and Market Status
4.4 Tekmira Pharmaceuticals
4.4.1 Tekmira Pharmaceuticals Profiles
4.4.2 Tekmira Pharmaceuticals Product Information
4.4.3 Tekmira Pharmaceuticals RNA Based Therapeutics Business Performance
4.4.4 Tekmira Pharmaceuticals RNA Based Therapeutics Business Development and Market Status
4.5 Benitec Biopharma Limited
…….TOC Continued

Canada Office:
302-20 Misssisauga Valley Blvd, Missisauga, L5A 3S1, Toronto
Contact Us
Email- info@supplydemandmarketresearch.com
Website- www.supplydemandmarketresearch.com
Phone Number: +919960204545

About us
We have a strong network of high powered and experienced global consultants who have about 10+ years of experience in the specific industry to deliver quality research and analysis.
Having such an experienced network, our services not only cater to the client who wants the basic reference of market numbers and related high growth areas in the demand side, but also we provide detailed and granular information using which the client can definitely plan the strategies with respect to both supply and demand side.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release RNA Based Therapeutics Market Expected to grow at a CAGR of CAGR of 28.5% By Key Players: Quark Pharmaceuticals, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Tekmira Pharmaceuticals here

News-ID: 1800295 • Views:

More Releases from Supply Demand Market Research

Drone Payloads Market Expected To Reach USD 33.86 Billion Globally.
Drone Payloads Market Expected To Reach USD 33.86 Billion Globally.
The market for drone payloads is expected to expand by 12.8% a year between 2023 and 2033, to reach USD 33.86 billion globally. The development of sophisticated drone payload systems, growing defense investments in unmanned technologies, expanding applications for drones, the market for location-based services, the need for better surveillance, and technological advancements with the growing use of AI for autonomous UAVs are all contributing factors to the growth. This 200-page
Healthcare Cold Chain Logistics Market Is Anticipated To Reach $29.72 Billion By 2033, Growing By 5.1% Annually
Healthcare Cold Chain Logistics Market Is Anticipated To Reach $29.72 Billion By …
According to our assessment, the global market for healthcare cold chain logistics is projected to increase by 5.1% a year over the next several years, reaching $29.72 billion by 2033. This 185-page research, which is highlighted with 88 tables and 92 figures, provides a 360-degree picture of the global market with thorough segmentations by Application, Service, Temperature, End User, and Region/Country, as indicated below. The report includes the annual revenue
Medical Bionics Is Anticipated To Reach USD $49.66 Billion By 2033
Medical Bionics Is Anticipated To Reach USD $49.66 Billion By 2033
The report gives a prognosis from 2024 to 2033 using 2023 as the base year, based on studies conducted for 2021-2023. The influence of COVID-19 and regional conflicts like the Russia-Ukraine war are taken into account while projecting the trajectory and outlook of the global market in optimistic, cautious, and balanced scenarios. According to a balanced assessment, the worldwide market for medical bionics is anticipated to increase by 11.2% a
Global Bionics Market Is Anticipated To Reach USD $59.94 Billion By 2033
Global Bionics Market Is Anticipated To Reach USD $59.94 Billion By 2033
The report gives a prognosis from 2024 to 2033 using 2023 as the base year, based on studies conducted for 2021-2023. The influence of COVID-19 and regional conflicts like the Russia-Ukraine war are taken into consideration while projecting the trajectory and outlook of the global market in optimistic, cautious, and balanced scenarios. According to a balanced assessment, the global bionics industry is projected to expand by 11.4% a year over

All 5 Releases


More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and